Literature DB >> 32104250

Knockdown of TOR signaling pathway regulator suppresses cell migration and invasion in non-small cell lung cancer via the regulation of epithelial-to-mesenchymal transition.

Xiang Xu1, Huangkai Zhu1,2, Minglei Yang1, Enkuo Zheng1, Yinjie Zhou1, Junjun Ni1, Rui Li1, Zhenhua Yang1, Ti He3, Guofang Zhao1.   

Abstract

Non-small cell lung cancer (NSCLC) is one of the most common cancer types worldwide. Previous studies have indicated that TOR signaling pathway regulator (TIPRL) is involved in the progression of NSCLC. However, the underlying mechanisms of the role of TIPRL in regulating NSCLC metastasis have remained largely elusive. In the present study, the expression pattern of TIPRL in NSCLC was analyzed using The Cancer Genome Atlas (TCGA) dataset. Furthermore, Kaplan-Meier curve analysis was performed to evaluate the prognostic value of TIPRL in NSCLC, using the Kaplan-Meier Plotter and TCGA datasets. Loss-of-function assays were performed to determine the effects of TIPRL on cell migration and invasion. The results suggested that TIPRL was upregulated in NSCLC and positively associated with an advanced Tumor-Node-Metastasis stage. A higher expression level of TIPRL was associated with shorter overall and disease-free survival times in patients with NSCLC. To the best of our knowledge, the present study was the first to report that TIPRL acts as a metastasis promoter in NSCLC. Silencing of TIPRL suppressed A549 cell migration and invasion. Mechanistically, the present study indicated that TIPRL knockdown significantly promoted epithelial-cadherin expression, whereas it suppressed twist and vimentin expression in A549 cells. In conclusion, the present analysis suggested that TIPRL may serve as a biomarker for the prognosis of NSCLC and as a future target for its treatment.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  TOR signaling pathway regulator; epithelial-to-mesenchymal transition; invasion; migration; non-small cell lung cancer

Year:  2019        PMID: 32104250      PMCID: PMC7027157          DOI: 10.3892/etm.2019.8358

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  28 in total

1.  Non-small-cell Lung Cancer With Brain Metastasis at Presentation.

Authors:  Saiama N Waqar; Pamela P Samson; Cliff G Robinson; Jeffrey Bradley; Siddhartha Devarakonda; Lingling Du; Ramaswamy Govindan; Feng Gao; Varun Puri; Daniel Morgensztern
Journal:  Clin Lung Cancer       Date:  2018-03-09       Impact factor: 4.785

2.  FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein.

Authors:  Yong Zhang; Xinxin Zhang; Mingxiang Ye; Pengyu Jing; Jie Xiong; Zhiping Han; Jing Kong; Mengyang Li; Xiaofeng Lai; Ning Chang; Jian Zhang; Jian Zhang
Journal:  Cancer Lett       Date:  2018-01-31       Impact factor: 8.679

3.  Inhibition of MKK7-JNK by the TOR signaling pathway regulator-like protein contributes to resistance of HCC cells to TRAIL-induced apoptosis.

Authors:  In Sung Song; Soo Young Jun; Hee-Jun Na; Hyun-Taek Kim; So Young Jung; Ga Hee Ha; Young-Ho Park; Liang Zhe Long; Dae-Yeul Yu; Jin-Man Kim; Joo Heon Kim; Jeong-Heon Ko; Cheol-Hee Kim; Nam-Soon Kim
Journal:  Gastroenterology       Date:  2012-07-27       Impact factor: 22.682

4.  WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.

Authors:  Don X Nguyen; Anne C Chiang; Xiang H-F Zhang; Juliet Y Kim; Mark G Kris; Marc Ladanyi; William L Gerald; Joan Massagué
Journal:  Cell       Date:  2009-07-02       Impact factor: 41.582

5.  The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer.

Authors:  Lingtao Jin; Jaemoo Chun; Chaoyun Pan; Avi Kumar; Guojing Zhang; Youna Ha; Dan Li; Gina N Alesi; Yibin Kang; Lu Zhou; Wen-Mei Yu; Kelly R Magliocca; Fadlo R Khuri; Cheng-Kui Qu; Christian Metallo; Taofeek K Owonikoko; Sumin Kang
Journal:  Mol Cell       Date:  2017-12-14       Impact factor: 17.970

Review 6.  H2AX a promising biomarker for lung cancer: a review.

Authors:  D Matthaios; P Hountis; P Karakitsos; D Bouros; S Kakolyris
Journal:  Cancer Invest       Date:  2013-11       Impact factor: 2.176

7.  TIPRL Inhibits Protein Phosphatase 4 Activity and Promotes H2AX Phosphorylation in the DNA Damage Response.

Authors:  Kimberly Romero Rosales; Michael A Reid; Ying Yang; Thai Q Tran; Wen-I Wang; Xazmin Lowman; Min Pan; Mei Kong
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

8.  Novel indazole-based small compounds enhance TRAIL-induced apoptosis by inhibiting the MKK7-TIPRL interaction in hepatocellular carcinoma.

Authors:  Ji-Yong Yoon; Jeong-Ju Lee; Sujin Gu; Myoung Eun Jung; Hyun-Soo Cho; Jung Hwa Lim; Soo Young Jun; Jun-Ho Ahn; Ju-Sik Min; Min-Hyuk Choi; Su-Jin Jeon; Yong-Jae Lee; Areum Go; Yun-Jeong Heo; Cho-Rok Jung; Gildon Choi; Kwangho Lee; Moon-Kook Jeon; Nam-Soon Kim
Journal:  Oncotarget       Date:  2017-11-03

9.  The regulatory role of APE1 in epithelial-to-mesenchymal transition and in determining EGFR-TKI responsiveness in non-small-cell lung cancer.

Authors:  Xiao Yang; Yu Peng; Xuan Jiang; Xianfeng Lu; Wei Duan; Shiheng Zhang; Nan Dai; Jinlu Shan; Yan Feng; Xuemei Li; Yi Cheng; Yuxin Yang; Laura Baugh; Gianluca Tell; Dong Wang; Mengxia Li
Journal:  Cancer Med       Date:  2018-08-14       Impact factor: 4.452

10.  In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.

Authors:  Caitlin L Grzeskowiak; Samrat T Kundu; Xiulei Mo; Andrei A Ivanov; Oksana Zagorodna; Hengyu Lu; Richard H Chapple; Yiu Huen Tsang; Daniela Moreno; Maribel Mosqueda; Karina Eterovic; Jared J Fradette; Sumreen Ahmad; Fengju Chen; Zechen Chong; Ken Chen; Chad J Creighton; Haian Fu; Gordon B Mills; Don L Gibbons; Kenneth L Scott
Journal:  Nat Commun       Date:  2018-07-16       Impact factor: 14.919

View more
  4 in total

Review 1.  Nanoformulations of flavonoids for diabetes and microvascular diabetic complications.

Authors:  Kopal Agarawal; Yogesh Anant Kulkarni; Sarika Wairkar
Journal:  Drug Deliv Transl Res       Date:  2022-05-30       Impact factor: 4.617

2.  Hsa_circ_0010235 functions as an oncogenic drive in non-small cell lung cancer by modulating miR-433-3p/TIPRL axis.

Authors:  Furui Zhang; Ruirui Cheng; Ping Li; Chunya Lu; Guojun Zhang
Journal:  Cancer Cell Int       Date:  2021-01-25       Impact factor: 5.722

Review 3.  Research progress on the relationship between the TOR signaling pathway regulator, epigenetics, and tumor development.

Authors:  Jiaen Sun; Minglei Yang; Weidi Zhao; Fajiu Wang; Liangwei Yang; Chuntao Tan; Tianjun Hu; Huangkai Zhu; Guofang Zhao
Journal:  Front Genet       Date:  2022-09-23       Impact factor: 4.772

Review 4.  Flavonoids on diabetic nephropathy: advances and therapeutic opportunities.

Authors:  Qichao Hu; Caiyan Qu; Xiaolin Xiao; Wenwen Zhang; Yinxiao Jiang; Zhao Wu; Dan Song; Xi Peng; Xiao Ma; YanLing Zhao
Journal:  Chin Med       Date:  2021-08-07       Impact factor: 5.455

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.